Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Biologic to Buy Controlling Interest in Competitor

publication date: Oct 2, 2008

China Biologic Products will pay $28.5 million to gain control of one of its competitors in the business of plasma-based pharmaceuticals. China Biologic will buy a 90% stake in Chongqing Dalin Biologic Technologies Co., Ltd. Dalin, in turn, owns a 54% equity interest in Qianfeng Biological Products Co., Ltd., which makes plasma-based products. Qianfeng is a bigger business that China Biologic. It has a 9.5% market share of China’s plasma-based biopharma business, while China Biologic can claim only 6.1%. More details...

Stock Symbol: (OTCBB: CBPO)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital